of ICET-A Network (International Network of Clinicians for
Endocrinopathies in Thalassemia and Adolescence Medicine), Ferrara,
2 Department of Pediatrics, Division of Endocrinology, Hamad General Hospital, Doha, Qatar and Department of Pediatrics, Division of Endocrinology, Alexandria University Children’s Hospital, Alexandria, Egypt.
3 Department of Haematology, College of Medicine and Health Sciences, Sultan Qaboos University, Sultanate of Oman.
4 Department of Diabetes & Endocrinology, Whittington Hospital, University College London, London, UK.
5 Emeritus Director in Pediatrics, Children’s Hospital “Santobono-Pausilipon,” Naples, Italy.
6 First Department of Paediatrics, National Kapodistrian University of Athens, Greece.
| This is an Open Access article distributed
under the terms of the Creative Commons Attribution License
(https://creativecommons.org/licenses/by-nc/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
To study the endocrine pancreas' function in transfusion-dependent
β-thalassemia (β-TDT) patients with a normal glucose tolerance test
(NGT) and hypoinsulinemia. In addition, the prospective long–term
follow-up using an annual oral glucose tolerance test (OGTT) to detect
any abnormality of glucose metabolism.
Patients and Methods
1. Clinical and laboratory characteristics of 7 patients with β- TDT at baseline.
2. Oral glucose tolerance test (OGTT) and first-phase insulin response
(FPIR), after IVGTT, at baseline in seven β- TDT patients.
|Table 3. Age at first documentation of glucose homeostasis impairment in 7 β- TDT patients followed yearly with an OGTT.|
|Figure 1. Outcome of 7 β-TDT patients with normal OGTT and hypoinsulinemia followed for 13-80 months.|
|Table 4. Follow-up of
indirect indices of insulin secretion and resistance at baseline and at
the diagnosis of IGT and DM in patients with β- TDT.